ROSAURA RIOS: Open Payments
NPI 1649907569 · MISSION, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,961 in 67 payments from 14 companies in 2025. Trend: 2023 $862 · 2024 $1,084 · 2025 $1,961
Food & beverage: $1,961
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 9 | $538 |
| Novo Nordisk Inc | 20 | $239 |
| Amgen Inc. | 7 | $229 |
| Corcept Therapeutics | 8 | $184 |
| Xeris Pharmaceuticals, Inc. | 6 | $177 |
| Insulet Corporation | 2 | $144 |
| Ascendis Pharma Endocrinology Inc | 3 | $144 |
| Mannkind Corporation | 1 | $98 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $82 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
Products named: Dexcom G6 Transmitter, Korlym, GVOKE HYPOPEN, Omnipod, Yorvipath, TEPEZZA, Wegovy, REPATHA.
Industry payments across TX — which companies pay providers there.
